Entera Bio, which is developing oral formulations of treatments for a thyroid condition and osteoporosis, announced terms for its IPO on Friday.
The Jerusalem, Israel-based company plans to raise $55 million by offering 5 million shares at a price range of $10 to $12. At the midpoint of the proposed range, Entera Bio would command a fully diluted market value of $141 million.
Entera Bio was founded in 2009 and plans to list on the Nasdaq under the symbol ENTX. Oppenheimer & Co. is the sole bookrunner on the deal. It is expected to price during the week of January 22, 2018.
